Literature DB >> 19467326

Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor.

Ying-Jun Chang1, Xiang-Yu Zhao, Ming-Rui Huo, Xiao-Jun Huang.   

Abstract

BACKGROUND AND OBJECTIVES: Adhesion molecules on T cells were implicated in the process of leukocyte migration and GVHD. The aim of this study was to investigate the profiles of adhesion molecule expression on naïve T cells in bone marrow grafts of healthy donors treated with G-CSF.
METHODS: The expression of four adhesion molecules, including VLA-4, ICAM-1, L-selectin, and LFA-1, on naïve T cells in G-CSF-primed bone marrow grafts (G-BM) from 35 healthy donors was analyzed using flow cytometry.
RESULTS: G-CSF administration significantly decreased the expression of VLA-4, ICAM-1, L-selectin, and LFA-1 on naïve CD4+ and CD8+ T cells in bone marrow grafts. Treating healthy donors with G-CSF significantly increased the percentages of interleukin-4 (IL-4) positive cells in naïve CD4+ and CD8+ T cell subsets, leading to polarization of bone marrow naïve CD4+ and CD8+ T cells from Th1 to Th2 phenotype.
CONCLUSIONS: Our results suggest that CD4+ and CD8+ naïve T cells in G-BM have lower intensities of expression of several adhesion molecules. The clinical significance of these alteration warrants further study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467326     DOI: 10.1016/j.trim.2009.05.005

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  8 in total

Review 1.  Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation.

Authors:  Xiaodong Mo; Xiaojun Huang
Journal:  Front Med       Date:  2013-07-20       Impact factor: 4.592

Review 2.  G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.

Authors:  U Deotare; G Al-Dawsari; S Couban; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

Review 3.  G-CSF-primed BM for allogeneic SCT: revisited.

Authors:  I Pessach; I Resnick; A Shimoni; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

4.  Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Ming-Rui Huo; Lan-Ping Xu; Dai-Hong Liu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  J Clin Immunol       Date:  2011-12-16       Impact factor: 8.317

5.  Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.

Authors:  Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier
Journal:  Regen Med       Date:  2014-04-28       Impact factor: 3.806

6.  Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts.

Authors:  Xiang-Yu Zhao; Yu-Tong Wang; Xiao-Dong Mo; Xiao-Su Zhao; Ya-Zhe Wang; Ying-Jun Chang; Xiao-Jun Huang
Journal:  J Transl Med       Date:  2015-05-07       Impact factor: 5.531

7.  Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients.

Authors:  Tingting Cheng; Yan Chen; Yi Liu; Xia Ma; Cong Zeng; Xu Chen; Shiyu Wang; Yajing Xu
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

8.  Multiomics Analysis Identifies SOCS1 as Restraining T Cell Activation and Preventing Graft-Versus-Host Disease.

Authors:  Huidong Guo; Ruifeng Li; Ming Wang; Yingping Hou; Shuoshuo Liu; Ting Peng; Xiang-Yu Zhao; Liming Lu; Yali Han; Yiming Shao; Ying-Jun Chang; Cheng Li; Xiao-Jun Huang
Journal:  Adv Sci (Weinh)       Date:  2022-05-18       Impact factor: 17.521

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.